Tibet Cheezheng Tibetan Medicine Co Ltd
SZSE:002287
Tibet Cheezheng Tibetan Medicine Co Ltd
SZSE:002287
Price:
24.05
CNY
-1.56%
Market Cap:
¥13.8B
Relative Value
The Relative Value of one
Tibet Cheezheng Tibetan Medicine Co Ltd
stock under the Base Case scenario is
21
CNY.
Compared to the current market price of 24.05 CNY,
Tibet Cheezheng Tibetan Medicine Co Ltd
is
Overvalued by 13%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
21
CNY
Overvaluation 13%
Multiples Across Competitors
Competitors Multiples
Tibet Cheezheng Tibetan Medicine Co Ltd Competitors
Tibet Cheezheng Tibetan Medicine Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SZSE:002287
|
12.9B CNY | 5.3 | 20.8 | 16.8 | 16.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
986.4B USD | 15.1 | 47.7 | 32.2 | 34.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
586.1B USD | 6.2 | 21.9 | 15.2 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
286.3B CHF | 4.7 | 30.5 | 12.9 | 15 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
235.3B GBP | 5.5 | 31.3 | 17.3 | 24.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
239B CHF | 5.5 | 22 | 13.6 | 17.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
301.2B USD | 4.6 | 16.5 | 10.3 | 12.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.5 | 13.5 | 9.9 | 11.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
157.3B USD | 2.5 | 20.2 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.4B USD | 2.6 | 17.5 | 6.8 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
